Read more
16:27 · 2 April 2025

BREAKING: Novavax shares tumble as FDA misses deadline For Covid-19 vaccine approval

Novavax
Shares
NVAX.US, Novavax Inc
-
-

The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.

This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.

 

Source: xStation 

29 October 2025, 21:00

📉 Microsoft Q1 2026 Earnings: Strong Numbers Mask Investor Anxiety Over AI Spending

29 October 2025, 20:43

🚀 Alphabet Soars on AI-Driven Results, Shares Rally 7% in After-Hours Trading

29 October 2025, 20:35

Meta drops 8% despite strong revenue growth 🔎

29 October 2025, 16:31

Upcoming Meta earnings: will the AI transformation be well received by the market? 🔎

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 1.7 Million investors from around the world